Johnson & Johnson is scheduled to report Q3 2026 results on October 13, with analyst consensus for Innovative Medicine sales near $16.6–16.7 billion, implying roughly 6–7% year-over-year growth after Q2’s $16.38 billion. Growth is expected to stem primarily from oncology products including Darzalex, Carvykti, Tecvayli, and Rybrevant, plus immunology gains from Tremfya and the Icotyde launch, and neuroscience contributions from Spravato and Caplyta. These are partially offset by steeper Stelara biosimilar erosion and competition affecting Imbruvica and other legacy assets. Recent positive long-term data for Icotyde and raised full-year guidance after Q2 support expectations for continued above-market segment performance, though MedTech softness and any margin or EPS shortfalls could influence overall sentiment ahead of the release.